EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis

[1]  David T. W. Jones,et al.  EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors , 2018, EMBO molecular medicine.

[2]  P. Hegde,et al.  Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer , 2018, The oncologist.

[3]  R. Bouchard,et al.  Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. , 2017, Cell reports.

[4]  M. Caligiuri,et al.  Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia , 2017, Proceedings of the National Academy of Sciences.

[5]  Zhi-su Liu,et al.  Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma , 2017, Oncotarget.

[6]  Zhi-su Liu,et al.  Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma. , 2017, Oncotarget.

[7]  P. Hegde,et al.  Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer , 2017, The oncologist.

[8]  Xue-jun Fan,et al.  HER3 and LINC00052 interplay promotes tumor growth in breast cancer , 2016, Oncotarget.

[9]  E. Yoon,et al.  EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells. , 2016, Cancer research.

[10]  K. Mujoo,et al.  Crk II silencing down-regulates IGF-IR and inhibits migration and invasion of prostate cancer cells , 2016, Biochemistry and biophysics reports.

[11]  K. Mujoo,et al.  Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer , 2016, Oncotarget.

[12]  R. Jordan,et al.  A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies , 2014, Molecular Cancer Therapeutics.

[13]  Xue-jun Fan,et al.  Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation , 2014, Breast Cancer Research.

[14]  S. Deutscher,et al.  Identification of a Peptide from In vivo Bacteriophage Display with Homology to EGFL6: A Candidate Tumor Vasculature Ligand in Breast Cancer , 2014, Journal of molecular biomarkers & diagnosis.

[15]  B. Zhou,et al.  The Role of Snail in EMT and Tumorigenesis. , 2013, Current cancer drug targets.

[16]  Y. Mao,et al.  Analysis of Gene Expression Profiling in Meningioma: Deregulated Signaling Pathways Associated with Meningioma and EGFL6 Overexpression in Benign Meningioma Tissue and Serum , 2012, PloS one.

[17]  T. Brabletz.  EMT and MET in metastasis: where are the cancer stem cells? , 2012, Cancer cell.

[18]  H. Stuhlmann,et al.  EGFL7: a unique angiogenic signaling factor in vascular development and disease. , 2012, Blood.

[19]  I. Mackenzie,et al.  Cancer stem cells and EMT in carcinoma , 2012, Cancer and Metastasis Reviews.

[20]  Hao Wang,et al.  EGFL6 Promotes Endothelial Cell Migration and Angiogenesis through the Activation of Extracellular Signal-regulated Kinase* , 2011, The Journal of Biological Chemistry.

[21]  F. Watt,et al.  The Basement Membrane of Hair Follicle Stem Cells Is a Muscle Cell Niche , 2011, Cell.

[22]  H. Stuhlmann,et al.  Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. , 2010, Blood.

[23]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[24]  R. Fisher,et al.  Angiogenesis Soluble Factors as Hepatocellular Carcinoma Noninvasive Markers for Monitoring Hepatitis C Virus Cirrhotic Patients Awaiting Liver Transplantation , 2007, Transplantation.

[25]  George Coukos,et al.  Tumor vascular proteins as biomarkers in ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Anil K Sood,et al.  Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. , 2007, Cancer research.

[27]  Didier Y. R. Stainier,et al.  The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation , 2004, Nature.

[28]  J. E. Ford,et al.  Cloning of a novel epidermal growth factor repeat containing gene EGFL6: expressed in tumor and fetal tissues. , 1999, Genomics.

[29]  A. Chung,et al.  Two Distinct Cell Attachment Sites in Entactin Are Revealed by Amino Acid Substitutions and Deletion of the RGD Sequence in the Cysteine-rich Epidermal Growth Factor Repeat 2 (*) , 1995, The Journal of Biological Chemistry.

[30]  Chengyuan Feng,et al.  EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma. , 2017, Cancer letters.

[31]  P. Hegde,et al.  Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. , 2017, The oncologist.